Fine‐scale geothermal heat flow in Antarctica can increase simulated subglacial melt estimates

Antarctic geothermal heat flow (GHF) affects the thermal regime of ice sheets and simulations of ice and subglacial meltwater discharge to the ocean, but remains poorly constrained. We use an ice sheet model to investigate the impact of GHF anomalies on subglacial meltwater production in the Aurora Subglacial Basin, East Antarctica. We find that spatially-variable GHF fields produce more meltwater than a constant GHF with the same background mean, and meltwater production increases as the resolution of GHF anomalies increases. Our results suggest that model simulations of this region systematically underestimate meltwater production using current GHF models. We determine the minimum basal heating required to bring the basal ice temperature to the pressure melting point, which should be taken together with the scale-length of likely local variability in targeting in-situ GHF field campaigns

Blood eosinophils and chronic obstructive pulmonary disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review.

This is the final version. Available from the American Thoracic Society via the DOI in this record. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) published its first report for the diagnosis and management of chronic obstructive pulmonary disease (COPD) in 2001 (1). Since then, GOLD has updated it yearly (2), the last time in 2022 (www.goldcopd.org). To do so, GOLD critically evaluates the new evidence since the previous publication and decides whether it merits (or not) inclusion in the most recent update. GOLD publishes specific recommendations and, sometimes, the main arguments behind them, but it often lacks space for a detailed discussion regarding the pros and cons behind each recommendation. To address this limitation, the Scientific Committee of GOLD decided to publish, separately from the main annual update, a series of papers that review and discuss topics of particular current interest for clinical practice. The GOLD 2019 report recommended using blood eosinophil counts (BEC) as part of a precision medicine strategy to identify the most suitable patients for inhaled corticosteroids (ICS) treatment (3). Recent publications have provided further evidence and insights concerning BEC in COPD. Here, we discuss the role of BEC as a COPD biomarker, focusing on new advances and summarizing the associated changes in the GOLD 2022 report (shown in Table 1)